原发性C3肾小球病与免疫复合物介导的膜增生性肾小球肾炎的自然病史及长期结局的相关临床因素
C3G与IC-MPGN共享多数基线和纵向特征,10年肾脏生存率无组织学亚型差异。发病年龄较大和活检后1年蛋白尿较高是肾衰竭的最强预测因素。
要点
- C3G与IC-MPGN的10年肾脏生存率无显著组织学亚型差异。
- 活检后1年蛋白尿≥1 g/24h与不良肾脏结局风险显著相关。
- 发病年龄较大和1年蛋白尿较高是肾衰竭的最强预测因素。
核心结论
- 发病年龄和蛋白尿水平与肾脏生存相关,应指导未来干预试验。
- C3G与IC-MPGN的10年肾脏生存率无统计学差异。
- 补体失调及补体基因罕见功能变异与结局无关。
研究设计与样本
- 意大利MPGN注册的回顾性分析,纳入349例活检证实的原发性C3G或IC-MPGN患者。
- 其中C3G 208例,IC-MPGN 141例;女性占41%,活检时超过半数年龄小于18岁。
- 采用单变量和多变量Cox回归及Kaplan-Meier生存分析评估风险关联。
- 复合终点包括ESKD(eGFR<15 ml/min per 1.73 m²、启动慢性透析或肾移植)、末次随访血清肌酐翻倍或肾脏相关死亡。
主要发现
- IC-MPGN患者基线蛋白尿高于C3G(中位4.0 vs 2.3 g/24小时,P<0.001)。
- 就诊时中位eGFR为83 ml/min per 1.73 m²。
- 活检后1年蛋白尿较高,尤其≥1 g/24小时,与不良肾脏结局风险显著相关。
- 儿童起病与更好的肾脏生存相关,但10年肾脏生存率在各组织学亚型间无统计学差异。
关键数值与推荐
- ESKD定义为eGFR<15 ml/min per 1.73 m²、启动慢性透析或肾移植。
- 复合终点还包括末次随访血清肌酐翻倍或肾脏相关死亡。
- 活检后1年蛋白尿≥1 g/24小时与不良肾脏结局风险显著相关。
- IC-MPGN基线蛋白尿中位4.0 g/24小时,C3G中位2.3 g/24小时(P<0.001)。
临床怎么用
- 对于原发性C3G/IC-MPGN患者,应关注发病年龄和活检后1年蛋白尿水平以评估肾脏预后。
- 活检后1年蛋白尿≥1 g/24小时提示不良肾脏结局风险较高,需加强监测和干预。
- 补体基因变异检测结果不宜单独用于预后判断。
局限性
- 回顾性研究设计。
- 来自意大利单一注册队列,外推性需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: This retrospective study analyzed clinical, histological, and biochemical data from a large cohort of participants with biopsy-proven primary C3 glomerulopathy/immune complex-mediated membranoproliferative GN. C3 glomerulopathy and immune complex-mediated membranoproliferative GN subjects shared most baseline and longitudinal features; 10-year kidney survival did not differ across histological subtypes. Older age at onset and higher proteinuria levels at 1 year from biopsy were the strongest predictors of kidney failure. BACKGROUND: Membranoproliferative glomerulonephritides (MPGNs) are defined by a typical glomerular histopathological pattern including C3 glomerulopathy (C3G) and immune complex-mediated MPGN (IC-MPGN). The overall prognosis is poor and the treatment options remain limited. Outcome predictors and reliable surrogate endpoints are critically needed for interventional trials. Herein, we described the natural history and analyzed clinical, histological and biochemical data from a large cohort of patients with primary C3G/IC-MPGN. METHODS: This is a retrospective analysis of patients with biopsy-proven primary C3G or IC-MPGN from the Italian Registry of MPGN. Demographic, clinical and histopathological data, molecular complement profiles, treatment patterns, and outcomes were collected. We performed univariable and multivariable Cox regressions and Kaplan-Meier survival analyses to assess risk associations with kidney disease progression. The composite endpoint included ESKD (defined by either eGFR <15 ml/min per 1.73 m 2 , initiation of chronic dialysis or kidney transplantation), doubling of serum creatinine at the last available follow-up, or death by kidney-related causes. RESULTS: Of the 349 patients identified, 208 had C3G and 141 IC-MPGN. Females were 41%, and over half were younger than 18 years old at time of biopsy. C3G and IC-MPGN patients shared most baseline and longitudinal features, with IC-MPGN patients presenting with higher baseline proteinuria (median 4.0 versus 2.3 g/24 hours, P < 0.001). Median eGFR at presentation was 83 ml/min per 1.73 m 2 . Twenty-six percent of patients progressed to ESKD over a median follow-up of 5 years from diagnosis. Higher proteinuria levels at 1 year from biopsy, particularly ≥1 g/24 hours, were significantly associated with a higher risk of adverse kidney outcomes. Pediatric onset was associated with better kidney survival, whereas kidney survival at 10 years did not statistically differ across histological subtypes. Complement dysregulation and rare functional variants in complement genes were not associated with outcomes. CONCLUSIONS: Our findings from a large and well-characterized cohort of individuals with primary C3G/IC-MPGN identify age at onset and proteinuria levels as associations with kidney survival, a finding that should inform future interventional trials.
引用
- Nanchen G, Marasà M, Breno M, et al. Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN. Clin J Am Soc Nephrol. 2025. PMID: 41433110. doi:10.2215/CJN.0000000953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。